Next Article in Journal
Pharmacy Education; Competency and Beyond
Previous Article in Journal
Travel Medicine Curricula across Canadian Pharmacy Programs and Alignment with Scope of Practice
Previous Article in Special Issue
Psychotropic and Opioid-Based Medication Use among Economically Disadvantaged African-American Older Adults
Open AccessReview

Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness

1
College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA 92831, USA
2
Health Sciences Library System, University of Pittsburgh, Pittsburgh, PA 15261, USA
*
Author to whom correspondence should be addressed.
Pharmacy 2020, 8(2), 103; https://doi.org/10.3390/pharmacy8020103
Received: 10 April 2020 / Revised: 9 June 2020 / Accepted: 11 June 2020 / Published: 16 June 2020
(This article belongs to the Special Issue Psychotropic Medication Adherence)
Background: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia. Methods: Literature searches were conducted in July 2019 in the PubMed database. Results: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of “mild disease”. Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use. Conclusions: A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology. View Full-Text
Keywords: adherence; antipsychotic; ingestible sensor; schizophrenia; serious mental illness adherence; antipsychotic; ingestible sensor; schizophrenia; serious mental illness
MDPI and ACS Style

Alipour, A.; Gabrielson, S.; Patel, P.B. Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness. Pharmacy 2020, 8, 103.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop